Host |
Mouse |
Clone |
Ber-EP4 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
EDTA, Trypsin or Fast Enzyme |
Positive control |
Kidney |
Dilution |
- |
Isotype |
Mouse IgG1 kappa |
Localization |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
Ber-EP4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM131 |
-
|
Host |
Monospecific Mouse |
Clone |
ZM131 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Colon carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human EP-CAM protein fragment from extracellular domain |
Localization |
Cytoplasm |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Zeta Corporation |
ZM131 |
1 ml |
Concentrate |
CE/IVD |
Z2441ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM131 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Colon carcinoma. |
Dilution |
- |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human EP-CAM protein fragment from extracellular domain |
Localization |
Cytoplasm |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Zeta Corporation |
ZM131 |
7 ml |
Ready-to-use |
CE/IVD |
Z2441MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM131 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Colon carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human EP-CAM protein fragment from extracellular domain |
Localization |
Cytoplasm |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Zeta Corporation |
ZM131 |
0.5 ml |
Concentrate |
CE/IVD |
Z2441MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM131 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Colon carcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human EP-CAM protein fragment from extracellular domain |
Localization |
Cytoplasm |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Zeta Corporation |
ZM131 |
0.1 ml |
Concentrate |
CE/IVD |
Z2441MT |
-
|
Host |
Mouse |
Clone |
CS1, CS2, CS3, CS4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
EBV Infected Tissue |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) (Cocktail) (LMP-1)
|
Diagnostic Biosystems |
CS1, CS2, CS3, CS4 |
1 ml |
Concentrate |
CE/IVD |
MOB194 |
-
|
Host |
Mouse |
Clone |
CS1, CS2, CS3, CS4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
EBV Infected Tissue |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) (Cocktail) (LMP-1)
|
Diagnostic Biosystems |
CS1, CS2, CS3, CS4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB194-01 |
-
|
Host |
Mouse |
Clone |
CS1, CS2, CS3, CS4 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
EBV Infected Tissue |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) (Cocktail) (LMP-1)
|
Diagnostic Biosystems |
CS1, CS2, CS3, CS4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB194-05 |
-
|
Host |
Mouse |
Clone |
CS1, CS2, CS3, CS4 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
EBV Infected Tissue |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) (Cocktail) (LMP-1)
|
Diagnostic Biosystems |
CS1, CS2, CS3, CS4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM128 |
-
|
Host |
Mouse |
Clone |
CS1-4 |
Format |
concentrate |
Method |
P |
Pretreatment |
HIER |
Positive control |
EBV infected tissue |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Recombinant fusion protein containing the sequence of bacterial beta-galactosidase and the carboxyl half of EBV-encoded LMP |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) LMP
|
Zeta Corporation |
CS1-4 |
1 ml |
concentrate |
RUO |
Z2094ML-R |
-
|
Host |
Mouse |
Clone |
CS1-4 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
HIER |
Positive control |
EBV infected tissue |
Dilution |
- |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Recombinant fusion protein containing the sequence of bacterial beta-galactosidase and the carboxyl half of EBV-encoded LMP |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) LMP
|
Zeta Corporation |
CS1-4 |
7 ml |
Ready-to-use |
RUO |
Z2094MP-R |
-
|
Host |
Mouse |
Clone |
CS1-4 |
Format |
concentrate |
Method |
P |
Pretreatment |
HIER |
Positive control |
EBV infected tissue |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Recombinant fusion protein containing the sequence of bacterial beta-galactosidase and the carboxyl half of EBV-encoded LMP |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) LMP
|
Zeta Corporation |
CS1-4 |
0.5 ml |
concentrate |
RUO |
Z2094MS-R |
-
|
Host |
Mouse |
Clone |
CS1-4 |
Format |
concentrate |
Method |
P |
Pretreatment |
HIER |
Positive control |
EBV infected tissue |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Recombinant fusion protein containing the sequence of bacterial beta-galactosidase and the carboxyl half of EBV-encoded LMP |
Localization |
Cytoplasm |
Epstein-Barr Virus (EBV) LMP
|
Zeta Corporation |
CS1-4 |
0.1 ml |
concentrate |
RUO |
Z2094MT-R |
-
|
Host |
Rabbit |
Clone |
ZR147 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Mamma carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment (around aa495-595) of human ER alpha protein (exact sequence is proprietary) |
Localization |
Nuclear |
ER
|
Zeta Corporation |
ZR147 |
1 ml |
Concentrate |
CE/IVD |
Z2691RL |
-
|
Host |
Rabbit |
Clone |
ZR147 |
Format |
ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Mamma carcinoma |
Dilution |
--- |
Isotype |
IgG |
Immunogen |
Recombinant fragment (around aa495-595) of human ER alpha protein (exact sequence is proprietary) |
Localization |
Nuclear |
ER
|
Zeta Corporation |
ZR147 |
7 ml |
ready-to-use |
CE/IVD |
Z2691RP |
-
|
Host |
Rabbit |
Clone |
ZR147 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Mamma carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment (around aa495-595) of human ER alpha protein (exact sequence is proprietary) |
Localization |
Nuclear |
ER
|
Zeta Corporation |
ZR147 |
0.5 ml |
Concentrate |
CE/IVD |
Z2691RS |
-
|
Host |
Rabbit |
Clone |
ZR147 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Mamma carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment (around aa495-595) of human ER alpha protein (exact sequence is proprietary) |
Localization |
Nuclear |
ER
|
Zeta Corporation |
ZR147 |
0.1 ml |
Concentrate |
CE/IVD |
Z2691RT |
-
|
Host |
Rabbit |
Clone |
SP68 |
Format |
Concentrate |
Reactivity |
BV, HM, MS, PG, RT |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon, NCSLC |
Dilution |
1:100 |
ERCC1
|
Zytomed Systems GmbH |
SP68 |
0.5 ml |
Concentrate |
RUO |
505-3682 |
-
|
Host |
Rabbit |
Clone |
SP68 |
Format |
Concentrate |
Reactivity |
BV, HM, MS, PG, RT |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon, NCSLC |
Dilution |
1:100 |
ERCC1
|
Zytomed Systems GmbH |
SP68 |
1 ml |
Concentrate |
RUO |
505-3684 |
-
|
Host |
Mouse |
Clone |
4F9 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Prostate, prostate cancer |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 |
Localization |
Nucleus, cytoplasm |
ERCC1
|
Biocare Medical |
4F9 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3147A |
-
|
Host |
Mouse |
Clone |
4F9 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Prostate, prostate cancer |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 |
Localization |
Nucleus, cytoplasm |
ERCC1
|
Biocare Medical |
4F9 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3147B |
-
|
Host |
Mouse |
Clone |
9FY |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
ERG postive prostate carcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
ERG
|
Biocare Medical |
9FY |
0.1 ml |
Concentrate |
CE/IVD |
CM421A |
-
|
Host |
Mouse |
Clone |
9FY |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
ERG postive prostate carcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
ERG
|
Biocare Medical |
9FY |
1 ml |
Concentrate |
CE/IVD |
CM421C |
-
|
Host |
Mouse |
Clone |
9FY |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
ERG postive prostate carcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
ERG
|
Biocare Medical |
9FY |
6 ml |
Ready-to-use |
CE/IVD |
PM421AA |
-
|
Host |
Rabbit |
Clone |
EP111 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Prostate carcinoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to residues on the C-terminus of the human ERG protein |
Localization |
Nucleus |
ERG
|
Diagnostic Biosystems |
EP111 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD034 |
-
|
Host |
Mouse + Rabbit |
Clone |
9FY + EP42 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
ERG positive prostate cancer with normal and/or PIN glands |
Dilution |
- |
Isotype |
Mouse IgG1 and Rabbit IgG |
Localization |
Nucleus (ERG) and cytoplasm (CK5) |
ERG + Cytokeratin 5 (ERG-2)
|
Biocare Medical |
9FY + EP42 |
6 ml |
Ready-to-use |
CE/IVD |
API437DSAA |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
WB |
Dilution |
1:1000 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic phosphopeptide corresponding to an amino acid sequence within MAPK which includes phosphorylated Thr202 and Tyr204 |
ERK1/2, phosphorylated Thr202/Tyr204 (Extracellular Regulated Kinase 1/2)
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
605-0106 |
-
|
Host |
Monospecific Mouse |
Clone |
ZM135 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Kidney. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant fragment of human EPO protein (around aa 28-162) |
Localization |
Cytoplasm |
Erythropoietin
|
Zeta Corporation |
ZM135 |
1 ml |
Concentrate |
CE/IVD |
Z2445ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM135 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Kidney. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant fragment of human EPO protein (around aa 28-162) |
Localization |
Cytoplasm |
Erythropoietin
|
Zeta Corporation |
ZM135 |
7 ml |
Ready-to-use |
CE/IVD |
Z2445MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM135 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Kidney. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant fragment of human EPO protein (around aa 28-162) |
Localization |
Cytoplasm |
Erythropoietin
|
Zeta Corporation |
ZM135 |
0.5 ml |
Concentrate |
CE/IVD |
Z2445MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM135 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Kidney. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Recombinant fragment of human EPO protein (around aa 28-162) |
Localization |
Cytoplasm |
Erythropoietin
|
Zeta Corporation |
ZM135 |
0.1 ml |
Concentrate |
CE/IVD |
Z2445MT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
EL |
Isotype |
Rabbit IgG |
Immunogen |
A mixture of all antigenic serotypes |
Escherichia coli (E. coli)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
605-0117 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
IF |
Dilution |
1:10.000 - 1:50.000 |
Isotype |
Rabbit IgG |
Immunogen |
A mixture of all antigenic serotypes |
Escherichia coli (E. coli) - FITC
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
605-0123C |
-
|
Host |
Mouse |
Clone |
6F11 |
Format |
Lyophilised |
Method |
F, P, WB |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
1:40 - 1:80 (P) |
Isotype |
Mouse IgG1 |
Immunogen |
Recombinant human estrogen receptor (alpha form) |
Estrogen Receptor
|
Zytomed Systems GmbH |
6F11 |
1 ml |
Lyophilised |
RUO |
605-0163 |
-
|
Host |
Mouse |
Clone |
6F11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
EDTA pH8 |
Positive control |
Breast Carcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
6F11 |
1 ml |
Concentrate |
CE/IVD |
MOB121 |
-
|
Host |
Mouse |
Clone |
6F11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
EDTA pH8 |
Positive control |
Breast Carcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
6F11 |
0.1 ml |
Concentrate |
CE/IVD |
MOB121-01 |
-
|
Host |
Mouse |
Clone |
6F11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
EDTA pH8 |
Positive control |
Breast Carcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
6F11 |
0.5 ml |
Concentrate |
CE/IVD |
MOB121-05 |
-
|
Host |
Mouse |
Clone |
6F11 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
EDTA pH8 |
Positive control |
Breast Carcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
6F11 |
6 ml |
Ready-to-use |
CE/IVD |
PDM048 |
-
|
Host |
Rabbit |
Clone |
SP1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
SP1 |
1 ml |
Concentrate |
CE/IVD |
RMAB001 |
-
|
Host |
Rabbit |
Clone |
SP1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
SP1 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB001-01 |
-
|
Host |
Rabbit |
Clone |
SP1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
SP1 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB001-05 |
-
|
Host |
Rabbit |
Clone |
SP1 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
SP1 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD001 |
-
|
Host |
Rabbit |
Clone |
SP1 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Breast Carcinoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Nucleus |
Estrogen Receptor
|
Diagnostic Biosystems |
SP1 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD001-25 |
-
|
Host |
Rabbit |
Clone |
SP129 |
Reactivity |
MS, RT, MK |
Method |
P, WB, FL |
Pretreatment |
EDTA |
Positive control |
Tonsil, prostate cancer |
Dilution |
1:100 |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
EZH2
|
Zytomed Systems GmbH |
SP129 |
0.1 ml |
- |
RUO |
505-4290 |
-
|
Host |
Rabbit |
Clone |
SP129 |
Reactivity |
MS, RT, MK |
Method |
P, WB, FL |
Pretreatment |
EDTA |
Positive control |
Tonsil, prostate cancer |
Dilution |
1:100 |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
EZH2
|
Zytomed Systems GmbH |
SP129 |
0.5 ml |
- |
RUO |
505-4292 |
-
|
Host |
Rabbit |
Clone |
SP129 |
Reactivity |
MS, RT, MK |
Method |
P, WB, FL |
Pretreatment |
EDTA |
Positive control |
Tonsil, prostate cancer |
Dilution |
1:100 |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
EZH2
|
Zytomed Systems GmbH |
SP129 |
1 ml |
- |
RUO |
505-4294 |
-
|
Host |
Rabbit |
Clone |
ZR150 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Breast carcinoma |
Dilution |
1:25-100 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
Localization |
Nuclear |
EZH2
|
Zeta Corporation |
ZR150 |
1 ml |
Concentrate |
CE/IVD |
Z2692RL |
-
|
Host |
Rabbit |
Clone |
ZR150 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Breast carcinoma |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
Localization |
Nuclear |
EZH2
|
Zeta Corporation |
ZR150 |
7 ml |
Concentrate |
CE/IVD |
Z2692RP |
-
|
Host |
Rabbit |
Clone |
ZR150 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Breast carcinoma |
Dilution |
1:25-100 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
Localization |
Nuclear |
EZH2
|
Zeta Corporation |
ZR150 |
0.5 ml |
Concentrate |
CE/IVD |
Z2692RS |
-
|
Host |
Rabbit |
Clone |
ZR150 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Breast carcinoma |
Dilution |
1:25-100 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human EZH2 protein |
Localization |
Nuclear |
EZH2
|
Zeta Corporation |
ZR150 |
0.1 ml |
Concentrate |
CE/IVD |
Z2692RT |
-
|